Skip to main content
  • Research article
  • Open access
  • Published:

Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial

A Correction to this article was published on 11 May 2021

This article has been updated



Although almost a year has passed since the Coronavirus disease 2019 (COVID-19) outbreak and promising reports of vaccines have been presented, we still have a long way until these measures are available for all. Furthermore, the most appropriate corticosteroid and dose in the treatment of COVID-19 have remained uncertain. We conducted a study to assess the effectiveness of methylprednisolone treatment versus dexamethasone for hospitalized COVID-19 patients.


In this prospective triple-blinded randomized controlled trial, we enrolled 86 hospitalized COVID-19 patients from August to November 2020, in Shiraz, Iran. The patients were randomly allocated into two groups to receive either methylprednisolone (2 mg/kg/day; intervention group) or dexamethasone (6 mg/day; control group). Data were assessed based on a 9-point WHO ordinal scale extending from uninfected (point 0) to death (point 8).


There were no significant differences between the groups on admission. However, the intervention group demonstrated significantly better clinical status compared to the control group at day 5 (4.02 vs. 5.21, p = 0.002) and day 10 (2.90 vs. 4.71, p = 0.001) of admission. There was also a significant difference in the overall mean score between the intervention group and the control group, (3.909 vs. 4.873 respectively, p = 0.004). The mean length of hospital stay was 7.43 ± 3.64 and 10.52 ± 5.47 days in the intervention and control groups, respectively (p = 0.015). The need for a ventilator was significantly lower in the intervention group than in the control group (18.2% vs 38.1% p = 0.040).


In hospitalized hypoxic COVID-19 patients, methylprednisolone demonstrated better results compared to dexamethasone.

Trial registration

The trial was registered with IRCT.IR (08/04/2020-No. IRCT20200204046369N1).

Peer Review reports


Coronavirus disease 2019 (COVID-19) caused by the novel coronavirus, also known as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), was declared as a global pandemic by the World Health Organization (WHO) on Mar 12, 2020. The disease, causing public health emergency worldwide, has been known to be the third outbreak of beta coronaviruses in the twenty-first century, after Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) [1,2,3,4]. The outbreak was first described in December 2019 as a cluster of acute respiratory illnesses in Wuhan, Hubei Province, China, which until January 15, 2021, infected over 93 million cases and caused over 2,000,000 deaths in 218 countries around the world [5]. Furthermore, the disease has impacted various aspects, from the healthcare system and workers, [6] diagnosis and management dilemmas and overlapping with other diseases [7,8,9], along with its significant mental and emotional impact on the public [10,11,12].

The relatively high infectivity, rapid progression of lung involvement, and absence of definite effective treatment all contribute to a need to design effective measures for management of COVID-19 based on the disease pathogenesis. Although many types of research and studies have contributed to the understanding of this disease and various empirical therapeutic options have been introduced on several operational methods, including the existing and new generation of antivirals, and traditional medicine, an effective therapeutic option has not yet been achieved for severe COVID-19 cases [13,14,15,16].

Earlier studies on SARS showed the overall cytokine dysregulation was the primary pathogenesis of organ dysfunction [17]. Thus, a critical window of opportunity for intervention is considered when status deterioration starts in patients with COVID-19, in which corticosteroids and other immunosuppressive agents can be advantageous, as was the case in experience with SARS and MERS [18,19,20].

In the United Kingdom, a major randomized clinical trial (RCT) indicated that the use of low-dose dexamethasone in ventilated COVID-19 patients, and to a lesser degree in patients in need of supplemental oxygen, reduced the mortality [21]. However, evidence for the intermediate-acting corticosteroid, methylprednisolone, has been limited to date [22, 23]. In most RCTs, this agent has been the primary corticosteroids used in the intensive care unit (ICU) management of ARDS. Thus, many ICU physicians feel comfortable with administrating this agent [24]. Mechanistically, methylprednisolone achieves higher lung tissue-to-plasma ratios in animal models than dexamethasone, which may thus be more effective for lung injury [24]. Also, previous studies have shown the effectiveness of methylprednisolone on treating SARS disease [25, 26]. Hence, we hypothesized that methylprednisolone could be more effective than other corticosteroids, particularly dexamethasone.

Thus, based on this information, we conducted a randomized control trial to evaluate the effect of methylprednisolone on the outcome of hospitalized COVID-19 patients and to compare it with the routinely used dexamethasone according to our national guideline.



Patients over 18 years that were hospitalized in the main teaching hospital of Shiraz University of Medical Sciences with SARS-CoV-2 infection, which was confirmed by real-time PCR, as described in our previous study [16], were enrolled. The inclusion criteria were hospitalized patients above 18 years of age, with an O2 saturation of less than 92 in room air on admission. The exclusion criteria were pregnancy, uncontrolled diabetes mellitus (DM), uncontrolled hypertension, patients who had previously been treated with steroids for any reason, or any contraindications of steroid administration, immunodeficiency disorders, O2 saturation of above 92 in room air, and lack of willingness to participate in the study.

Study design

This study is a stratified triple-blind RCT. Patients were enrolled at Faghihi hospital in Shiraz, Iran, between August 2020 and November 2020, and randomly allocated in a 1:1 ratio to receive a 10-day course of methylprednisolone or dexamethasone with the standard care [27, 28]. Random allocation using the block randomization method was performed in all four branches of the strata, based on two prognostic factors such as age (< 55 and ≥ 55) and disease severity based on O2 saturation (< 85 and ≥ 85). During the procedure, the allocation remained concealed. The patient, assessor, and analyzer in the two groups did not have access to the randomization list and type of administered drug (Triple blind). All patients received standard care. Furthermore, the intervention group received 2 mg per kilogram of methylprednisolone intravenously daily which was infused over 60 min, and tapered to half dosage every five days. Methylprednisolone treatment was stopped in any patient who faced severe elevations in blood pressure (systolic blood pressure ≥ 180 mmHg and/or diastolic blood pressure ≥ 120 mmHg) or uncontrolled blood sugar (need of long-acting insulin more than 0.5 U/kg for maintaining blood glucose less than 180 mg per dL for hospitalized patients with type 2 diabetes). All patients who were randomized to the control group received 6 mg of dexamethasone intravenously daily for 10 days. Figure 1 demonstrates the CONSORT flow diagram of our study.

Fig. 1
figure 1

CONSORT Flow diagram of a randomized clinical trial of Methylprednisolone vs. Dexamethasone in patients with COVID-19

Clinical and laboratory monitoring

Patient evaluations included demographic features, underlying disease, smoking status, and oxygen saturation, type of oxygen supplementation, respiratory rate, and routine physical exams. To compare the outcome of patients’ clinical status in the two groups, a guide provided by the WHO was used, called the Ordinal Scale for Clinical Improvement (OSCI), using a 9-point scale, ranging from 0 as no clinical or virological evidence of infection (uninfected) to 8 assigned as death [29]. Also, the need for a ventilator during the study, length of hospital stays, and death were noted. The worst score was recorded if the health condition of patients who stayed hospitalized changed on a specific day. On day 10, a final assessment was performed. However, patients were followed for the 28th-day outcome in the outpatient clinic after discharge.

End points

The primary endpoints were the all-cause mortality in 28 days and clinical status after 5 as well as 10 days after enrollment with 9-point WHO ordinal scale.

The secondary endpoints were need for invasive mechanical ventilation and admission to ICU. Predetermined exploratory endpoints were the duration of hospital stay and finally, hospital death during the 28 days after enrollment. The proportion of patients with these endpoints was also evaluated on days 5 and 10.


Assuming 95% confidence level (first type alpha error 5%) and 80% power as well as considering the observation of at least 0.30 and expecting differences in treatment results between the intervention (0.25) and control (0.55) groups, we calculated that a total of 82 COVID-19 patients (i.e. 41 cases in the methylprednisolone group and 41 in the control group) would be required for the analysis (Fleiss with CC). Measurement data were described by mean ± standard deviation (SD) and numerical data were described by number (%). Statistical differences were assessed using Pearson’s chi-square or Fisher’s exact tests as categorical variables, as appropriate. The paired-samplet-test was used to evaluate the changes of clinical indices before and after the administration of methylprednisolone. All analyses were performed in SPSS version 26.0 and p < 0.05 was considered statistically significant.

Ethical approval

The study was approved by the ethics committee of Shiraz University of Medical Sciences (SUMS.REC.1399.014), the institutional review board, and Iranian Registry of Clinical Trials (IRCT20200204046369N1 registered on 08/04/2020). It was conducted in compliance with local regulatory requirements, Good Clinical Practice (GCP), and the Declaration of Helsinki [30]. Written informed consent was obtained from all patients or their legally authorized representatives.


A total of 86 patients were enrolled in this clinical trial, with 44 receiving methylprednisolone alongside the standard treatment, while 42 receiving dexamethasone beside the standard treatment who were assigned as the control group. Table 1 reports the baseline data of the patients in our study.

Table 1 Demographic status of subjects in the intervention and control groups at baseline (N = 86)

As listed in Table 1, there was no significant variation between the two groups based on demographic features, comorbid diseases, and disease severity on admission day (O2 saturation).

The patients were evaluated at day 0 (on admission), day 5, and day 10 and compared based on OSCI. As indicated in Table 2, there was no significant correlation between the OSCI score in the intervention and control groups on admission (4.79 vs. 4.69, p = 0.504). However, the intervention group demonstrated significantly lower OSCI than the control group at day 5 (4.02 vs. 5.21, p = 0.002) and day 10 (2.90 vs. 4.71, p = 0.001) of admission.

Table 2 Mean and standard deviation of clinical status in the intervention and control groups at days 0, 5 and 10

To examine the clinical course on days 0, 5, and 10, we utilized the repeated measure model. There was a significant effect of time on clinical status, Wilks’ Lambda = 0.659, F (2.83) = 21.450, p > 0.001. There was also a significant difference in the overall mean score between the intervention group (3.909 with a range of 3.458–4.360) and the control group (4.873 with a range of 4.411–5.335) (p = 0.004).

The repeated ANOVA measurement showed the clinical status score changed significantly during the follow-up for all participants (within-group comparison), p = 0.001. Also, there was a significant difference after the follow-up between the two groups (p = 0.001). (Fig. 2).

Fig. 2
figure 2

Diagram of clinical status in the intervention (methyl-prednisolone) and control groups

In terms of mortality, the control group reported 15 cases (37.5%), while in the intervention group, eight patients died (18.6%); however, this difference did not reach statistical significance (p = 0.076).

The duration of hospital stay was also compared. To make an accurate estimate, we excluded the patients who died during the hospital course. Based on the remaining number of patients, the mean length of hospital stay was 7.43 ± 3.64 days and 10.52 ± 5.47 days in the intervention and control groups, respectively (p = 0.015).

Another outcome indicator was the need to use a ventilator. The need for a ventilator was significantly lower in the intervention group (18.2%) than in the control group (38.1%) (p = 0.040).


Since the emergence of COVID-19, the world population has faced unprecedented stress. Although almost a year has passed since the outbreak of the disease and promising reports of vaccines have been presented, we still have a long way until these measures are available worldwide. Until then, the virus continues to claim many victims and seize many lives, with undesirably high mortality rates among these patients. Thus, physicians have been required to make treatment decisions without substantial evidence during this period. However, since the first reports of the disease in various parts of the world, many data have been gathered and reported to understand the disease characteristics and therapeutic management. For instance, reported data have helped the scientific community understand the role of the patients’ immune response and its infectious characteristics.

In this study, we aimed to evaluate the therapeutic effect of methylprednisolone as an add-on treatment to the standard treatment regimen of hospitalized COVID-19 patients. Our data were compared with a previously accepted corticosteroid treatment, dexamethasone, based on the hypothesis that methylprednisolone has higher lung penetration [31, 32]; thus, it can act as a better immunosuppressive agent in the treatment of COVID-19 and in improvement of respiratory complications. Following this theory, our data showed a significant beneficial effect of methylprednisolone in the patients’ treatment course and outcome, in terms of clinical status score (based on ordinal scale score), hospitalization duration, and need for mechanical ventilation. Also, the mortality rates were lower in patients who received methylprednisolone than those who received dexamethasone (8 vs. 15), though this did not reach statistical significance. It is possible that with a large sample size, statistically significant differences may have been found.

Various observational studies have evaluated the beneficial effects of corticosteroids in the treatment of COVID-19 as these agents are widely available, inexpensive, and are easy to use [33,34,35]. Since there had been conflicting results in other viral pneumonia regarding the safety and beneficial effects of corticosteroids, the WHO in the early period of the pandemic published recommendations against the routine use of these agents in managing patients with COVID-19 [26]. However, it is well known that glucocorticoid agents are thought to be useful in stopping the inflammatory storm by suppressing pro-inflammatory gene expression and reducing cytokine levels if used at the appropriate time in the disease course [36]. For instance, some studies reported an increase in mortality and prolonged duration of viral clearance using corticosteroids in MERS and Influenza [20, 37]. Furthermore, in early studies regarding COVID-19, variations regarding the dosage and administration of corticosteroids have led to inconclusive results about the efficiency of these agents [19]. However, later studies have proved the efficacy of methylprednisolone in patients suffering from COVID-19.

In a randomized clinical trial done by Edalatifard et al., the effectiveness of intravenous methylprednisolone pulse was evaluated [38]. In the mentioned study, those who received methylprednisolone had a lower mortality rate and higher survival time than the control group. Moreover, an increase in O2 saturation and BORG scale was observed at the end of the study alongside lesser clinical findings such as myalgia, chest pain, cough, and gastrointestinal symptoms in those who were treated with methylprednisolone compared to those who received standard care. In laboratory findings, the case group experienced a reduction in the CRP level and an increase in the platelet count. Although the dosage and duration of methylprednisolone administration of the mentioned study were different from those of our research, their results are concordant. In our study, those who received standard care were administered dexamethasone in contrast to the mentioned study above, which would also emphasize the superiority of methylprednisolone over administering dexamethasone alone.

In a retrospective cohort study done by Wang et al., evaluating the treatment of patients suffering from COVID-19 with low dose methylprednisolone with short term duration, patients who received 1-2 mg/kg/day methylprednisolone for 5–7 days had shorter hospital course duration, less need for mechanical ventilation, but there was no difference in mortality rate compared to those who received standard care, which is in line with our results [39]. Further studies have also reported a reduction of poor outcomes in patients receiving methylprednisolone [40,41,42].

In our study, both treated groups received corticosteroids (the control group received dexamethasone); however, those who received methylprednisolone ended up having better outcomes and less dependency on mechanical ventilation. This data suggests that better penetration of methylprednisolone in the lungs compared to dexamethasone may have led to the observed improved outcomes; as also suggested by the multiple studies demonstrating better penetrance of methylprednisolone in the lung tissue compared to other corticosteroids [43,44,45]. The differences found may instead be explained by the relatively higher dose of corticosteroid given that the estimated 6 mg of dexamethasone a day is equivalent to approximately 32 mg of methylprednisolone [46]. This suggests the control group was receiving about 0.5 mg/kg day based on a standard 70 kg male and thus the methylprednisolone group received a more potent dose. Whether due to differences in dosage or medication, 2 mg/kg of methylprednisolone led to better outcomes in hypoxic hospitalized COVID-19 patients compared to 6 mg/day of dexamethasone.

Although managing patients suffering from COVID-19 with glucocorticoids may have some complications such as superimposed infection, immunosuppression, and hyperglycemia, recent studies reported no significant complications in their study course. However, hyperglycemia was more frequent in those who received methylprednisolone, managed without substantial complications [38,39,40, 42]. Moreover, it is suggested that the full dose of proper antibiotic therapy and immune regulators such as human immunoglobulin should be used to enhance the patients’ immunity in cases with complications [39].

This study had several limitations, including the small sample size in each group and limited data regarding the complications, lab data, and computed tomography features. Given the limitations of the study, further randomized controlled trials are required with larger sample sizes and later follow-ups to evaluate the beneficial effect of methylprednisolone in patients with COVID-19 pneumonia.


In hospitalized patients suffering from COVID-19 pneumonia, the administration of 2 mg/kg per day of intravenous methylprednisolone compared to treatment with 6 mg/day of dexamethasone, led to a reduction in the hospital length of stay, need for mechanical ventilation, and improved clinical status at days 5 and 10.

Availability of data and materials

All de-identified data and statistical codes used to generate the results will be available on request to the corresponding author.

Change history



Consolidated standards of reporting trials


Coronavirus disease 2019


Diabetes mellitus


Good Clinical Practice


Intensive care unit


Middle East respiratory syndrome coronavirus


Ordinal Scale for Clinical Improvement


Randomized controlled trial


Severe Acute Respiratory Syndrome Coronavirus


Severe Acute Respiratory Syndrome Coronavirus-2


Standard deviation


  1. Eurosurveillance Editorial Team. Note from the editors: World Health Organization declares novel coronavirus (2019-nCoV) sixth public health emergency of international concern. Euro Surveill. 2020;25(5):200131e.

    Article  PubMed Central  Google Scholar 

  2. World Health Organization. WHO announces COVID-19 outbreak a pandemic, 2020. Available from: Accessed 7 December 2020.

  3. World Health Organization. Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV). 2020. Available from: Accessed 11 December 2020.

  4. World Health Organization. Clinical management of severe acute respiratory infection when Middle East respiratory syndrome coronavirus ( MERS-CoV) infection is suspected: interim guidance. 2019. Available from: Accessed 3 January 2021.

  5. Worldometer. COVID-19 Coronavirus Pandemic. 2020. Available from: Accessed 15 January 2021.

  6. Sabetian G, Moghadami M, Hashemizadeh Fard Haghighi L, Shahriarirad R, Fallahi MJ, Asmarian N, et al. COVID-19 infection among healthcare workers: a cross-sectional study in southwest Iran. Virol J. 2021;18(1):58.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Lotfi M, Sefidbakht S, Moghadami M, Iranpour P, Emami Y, Jafari SH, et al. Introduction of a Radiologic Severity Index for the 2019 Novel Corona Virus (COVID-19). 2020. doi:

  8. Shahriarirad R, Sarkari B. COVID-19: clinical or laboratory diagnosis? A matter of debate. Trop Dr. 2020;51(1):131–2.

    Article  Google Scholar 

  9. Ashraf MA, Keshavarz P, Hosseinpour P, Erfani A, Roshanshad A, Pourdast A, et al. Coronavirus disease 2019 (COVID-19): a systematic review of pregnancy and the possibility of vertical transmission. J Reprod Infertil. 2020;21(3):157–68.

    PubMed  PubMed Central  Google Scholar 

  10. Mirahmadizadeh A, Ranjbar K, Shahriarirad R, Erfani A, Ghaem H, Jafari K, et al. Evaluation of students' attitude and emotions towards the sudden closure of schools during the COVID-19 pandemic: a cross-sectional study. BMC Psychol. 2020;8(1):1–7.

    Article  Google Scholar 

  11. Shahriarirad R, Erfani A, Ranjbar K, Bazrafshan A, Mirahmadizadeh A. The mental health impact of COVID-19 outbreak: a Nationwide survey in Iran. Int J Ment Health Syst. 2021;15(1):19.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Erfani A, Shahriarirad R, Ranjbar K, Mirahmadizadeh A, Moghadami M. Knowledge, attitude and practice toward the novel coronavirus (COVID-19) outbreak: a population-based survey in Iran. Bull World Health Organ. 2020.

  13. Cheng ZJ, Shan J. 2019 novel coronavirus: where we are and what we know published correction appears in infection. Infection. 2020;48(2):155–63.

    Article  CAS  PubMed  Google Scholar 

  14. Young B, Tan TT, Leo YS. The place for remdesivir in COVID-19 treatment. Lancet Infect Dis. 2021;21(1):20–1.

    Article  CAS  PubMed  Google Scholar 

  15. Vetter P, Kaiser L, Calmy A, Agoritsas T, Huttner A. Dexamethasone and remdesivir: finding method in the COVID-19 madness. Lancet Microbe. 2020;1(8):e309–10.

    Article  CAS  PubMed  Google Scholar 

  16. Shahriarirad R, Khodamoradi Z, Erfani A, Hosseinpour H, Ranjbar K, Emami Y, et al. Epidemiological and clinical features of 2019 novel coronavirus diseases (COVID-19) in the south of Iran. BMC Infect Dis. 2020;20(1):1–12.

    Article  CAS  Google Scholar 

  17. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med. 2006;3(9):e343.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Arabi YM, Mandourah Y, Al-Hameed F, et al. Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome. Am J Respir Crit Care Med. 2018;197(6):757–67.

    Article  PubMed  Google Scholar 

  21. Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384(8):693–704.

    Article  CAS  PubMed  Google Scholar 

  22. Williams DM. Clinical pharmacology of corticosteroids. Respir Care. 2018;63(6):655–70.

    Article  PubMed  Google Scholar 

  23. Sterne J, Murthy S, Diaz J, Slutsky A, Villar J, Angus D, et al. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: A meta-analysis. JAMA. 2020;324(13):1330–41.

  24. Annane D, Pastores SM, Arlt W, Balk RA, Beishuizen A, Briegel J, et al. Critical illness-related corticosteroid insufficiency (CIRCI): a narrative review from a Multispecialty Task Force of the Society of Critical Care Medicine (SCCM) and the European Society of Intensive Care Medicine (ESICM). Intensive Care Med. 2017;43(12):1781–92.

  25. Hui DS, Sung JJ. Severe acute respiratory syndrome. Chest. 2003;124(1):12–5.

    Article  PubMed  Google Scholar 

  26. Papamanoli A, Yoo J, Grewal P, Predun W, Hotelling J, Jacob R, et al. High-Dose Methylprednisolone in Nonintubated Patients with Severe COVID-19 Pneumonia. Eur J Clin Investig. 2020:e13458.

  27. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at Accessed 1 Augost 2020.

  28. The Islamic Republic of Iran Medical Council. Guide to Diagnosis and Treatment of Covid 19. 2020. Available from: Accessed 10 Augost 2020.

  29. World Health Organization. WHO R&D Blueprint-Novel Coronavirus COVID-19 Therapeutic Trial Synopsis. 2020. Available from: Accessed 13 January 2021.

  30. Association WM. World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–4.

    Article  CAS  Google Scholar 

  31. Meduri GU, Siemieniuk RAC, Ness RA, Seyler SJ. Prolonged low-dose methylprednisolone treatment is highly effective in reducing duration of mechanical ventilation and mortality in patients with ARDS. J Intensive Care. 2018;6(1):53.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Braude AC, Rebuck AS. Prednisone and methylprednisolone disposition in the lung. Lancet. 1983 Oct 29;2(8357):995–7.

    Article  CAS  PubMed  Google Scholar 

  33. Fadel R, Morrison AR, Vahia A, Smith ZR, Chaudhry Z, Bhargava P, et al. COVID-19 management task force. Early short-course corticosteroids in hospitalized patients with COVID-19. Clin Infect Dis. 2020;71(16):2114–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Alzghari SK, VSJJoCV A. Supportive treatment with tocilizumab for COVID-19: a systematic review. J Clin Virol. 2020;127:104380. 32353761.

  35. Salvi R, Patankar P. Emerging pharmacotherapies for COVID-19. Biomed Pharmacother. 2020;128:110267.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Darwish I, Mubareka S, Liles WC. Immunomodulatory therapy for severe influenza. Expert Rev Anti-Infect Ther. 2011;9(7):807–22.

    Article  CAS  PubMed  Google Scholar 

  37. Lansbury LE, Rodrigo C, Leonardi-Bee J, Nguyen-Van-Tam J, Shen LW. Corticosteroids as adjunctive therapy in the treatment of influenza: an updated Cochrane systematic review and meta-analysis. Crit Care Med. 2020;48(2):e98–e106.

    Article  PubMed  Google Scholar 

  38. Edalatifard M, Akhtari M, Salehi M, Naderi Z, Jamshidi A, Mostafaei S, et al. Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial. Eur Respir J. 2020;56(6):2002808.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Wang Y, Jiang W, He Q, Wang C, Wang B, Zhou P, et al. A retrospective cohort study of methylprednisolone therapy in severe patients with COVID-19 pneumonia. Signal Transduct Target Ther. 2020;5(1):57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Corral L, Bahamonde A, de las Revillas FA, Gomez-Barquero J, Abadia-Otero J, Garcia-Ibarbia C, et al. GLUCOCOVID: A controlled trial of methylprednisolone in adults hospitalized with COVID-19 pneumonia. MedRxiv. 2020. doi:

  41. Jeronimo CMP, Farias MEL, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, et al. Methylprednisolone as adjunctive therapy for patients hospitalized with COVID-19 (Metcovid): a randomised, double-blind, phase IIb, placebo-controlled trial. Clin Infect Dis. 2020:ciaa1177.

  42. Nelson BC, Laracy J, Shoucri S, Dietz D, Zucker J, Patel N, et al. Clinical outcomes associated with methylprednisolone in mechanically ventilated patients with COVID-19. Clin Infect Dis. 2020:ciaa1163.

  43. Braude A, Rebuck AJTL. Prednisone and methylprednisolone disposition in the lung. Lancet. 1983;2(8357):995–7.

    Article  CAS  PubMed  Google Scholar 

  44. Hirano T, Homma M, Oka K, Tsushima H, Niitsuma T, Hayashi TJI. Individual variations in lymphocyte-responses to glucocorticoids in patients with bronchial asthma: comparison of potencies for five glucocorticoids. Immunopharmacology. 1998;40(1):57–66.

    Article  CAS  PubMed  Google Scholar 

  45. Vichyanond P, Irvin CG, Larsen GL, Szefler SJ, MRJJoa H, Immunology C. Penetration of corticosteroids into the lung: evidence for a difference between methylprednisolone and prednisolone. J Allergy Clin Immunol. 1989;84(6 Pt 1):867–73.

    Article  CAS  PubMed  Google Scholar 

  46. Mager DE, Lin SX, Blum RA, Lates CD, Jusko WJ. Dose equivalency evaluation of major corticosteroids: pharmacokinetics and cell trafficking and cortisol dynamics. J Clin Pharmacol. 2003;43(11):1216–27.

    Article  CAS  PubMed  Google Scholar 

Download references


The authors would like to thank Shiraz University of Medical Sciences, Shiraz, Iran, and also the Center for Development of Clinical Research of Nemazee Hospital and Dr. Nasrin Shokrpour for editorial assistance. This study was the subject of MD dissertation of Keivan Ranjbar (Thesis No. 22403).


No specific funding was obtained for this study.

Author information

Authors and Affiliations



MM, MJF and VK contributed to the conception or design of the work. MHGS, AE and KR contributed to the acquisition and analysis of the data. RS, AM and KR contributed to the interpretation of the data for the work. AE, ZK, RS and KR drafted the work. MM and KR revised it critically for important intellectual contents. All authors approved the final version to be published.

Corresponding author

Correspondence to Mohsen Moghadami.

Ethics declarations

Ethics approval and consent to participate

This study obtained ethics approval from the Institutional Review Board of Shiraz University of Medical Sciences (SUMS.REC.1399.014). The study was registered on IRCT.IR with the following identifier: IRCT20200204046369N1 on 08/04/2020. Written informed consent was obtained from all patients or their legally authorized representatives.

Consent for publication

Not applicable.

Competing interests

All authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

an error was identified in the Abstract section. The incorrect sentence is: The patients were randomly allocated into two groups to receive either methylprednisolone (2 mg/kg/day; intervention group) or dexamethasone (6 mg/kg/day; control group). The correct sentence is: The patients were randomly allocated into two groups to receive either methylprednisolone (2 mg/kg/day; intervention group) or dexamethasone (6 mg/day; control group). The original article has been corrected

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ranjbar, K., Moghadami, M., Mirahmadizadeh, A. et al. Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial. BMC Infect Dis 21, 337 (2021).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: